Volume 24, Number 4—April 2018
Research
Artemisinin-Resistant Plasmodium falciparum with High Survival Rates, Uganda, 2014–2016
Table 1
Characteristics | Enrolled | RSA results obtained |
---|---|---|
No. patients | 249 | 194 |
2014 Oct | 16 | 15 |
2015 May | 74 | 43 |
2015 Oct | 63 | 51 |
2016 June |
96 |
85 |
Sex, no. patients | ||
M | 126 | 92 |
F |
123 |
102 |
Age, y | ||
Median (IQR) |
3.0 (2.0–4.5) |
2.9 (2.0–4.4) |
Fever >37.5°C | ||
No. (%) patients | 207 (83) | 177 (92) |
Median (IQR) body
temperature, °C |
39 (38.0–39.4) |
39 (38.3–39.5) |
Signs and symptoms, % patients | ||
Cough | 22 | 29 |
Vomiting | 21 | 25 |
Abdominal pain | 11 | 21 |
Headache | 10 | 19 |
Diarrhea | 7 | 10 |
Convulsion |
7 |
8 |
Day 0 parasitemia, median (IQR), % | 1.71 (0.17–4.13) | 1.95 (0.85–4) |
*IQR, interquartile range; RSA, ring-stage survival assay.
1Current affiliation: National Institute of Advanced Industrial Science and Technology, Kagawa, Japan.
2Current affiliation: Mildmay Uganda-KAMPALA, Kampala, Uganda.
3Current affiliation: Gunma University, Gunma, Japan.
4Deceased.
Page created: March 16, 2018
Page updated: March 16, 2018
Page reviewed: March 16, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.